MGI Pharma Boosts Hematology Pipeline With AkaRx Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II thrombocytopenia candidate AKR-501 has revenue potential in excess of $1 billion in the U.S., MGI says.
You may also be interested in...
Sale Speculation Begins As MGI Pharma Considers ‘Strategic Alternatives’
Carl Icahn’s recent purchase of more than 600,000 shares feeds the rumor mill.
Sale Speculation Begins As MGI Pharma Considers ‘Strategic Alternatives’
Carl Icahn’s recent purchase of more than 600,000 shares feeds the rumor mill.
MGI Pharma Files Aquavan NDA
Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.